NCT04971551View on ClinicalTrials.gov

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2025

Conditions

Acute Graft-Versus-Host Disease

Interventions

DRUG

Jaktinib Hydrochloride Tablets

Oral on an empty stomach

Trial Locations (1)

Unknown

Henan Tumor Hospital, Zhengzhou

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY